Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617855 | 0.92 | KDR (0.49) | HPGDMMP13RECQLCYP3A4CYP1A2 | |
| SCHEMBL1617729 | 0.84 | KDR (0.49) | METKDRCSF1RPDGFRB | |
| SCHEMBL1617635 | 0.82 | AXL (0.43) | ALDH1A1METKDRCSF1RPDGFRB | |
| SCHEMBL1618304 | 0.81 | KDR (0.42) | METKDRCSF1RPDGFRB | |
| SCHEMBL1618225 | 0.81 | KDR (0.47) | METKDRCSF1RPDGFRB | |
| SCHEMBL1618265 | 0.78 | SELE (0.43) | CYP3A4CYP1A2METKDRCYP2D6 | |
| SCHEMBL1618110 | 0.77 | MET (0.51) | METKDRPDGFRBMAPK14 | |
| SCHEMBL1617951 | 0.77 | KDR (0.45) | METKDRPDGFRB | |
| SCHEMBL12716099 | 0.76 | KDR (0.42) | CYP3A4METKDRCSF1RPDGFRB | |
| SCHEMBL12716052 | 0.75 | KDR (0.54) | METKDRCSF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381824-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | claimed |
| JP-2007516273-A | — | — | 2007-06-21 | — | — | JP | claimed |
| EP-1699780-A1 | NOVEL QUINOLINE DERIVATIVES | Pfizer, Inc. (US) | 2006-09-13 | — | — | EP | claimed |
| WO-2005063739-A1 | NOVEL QUINOLINE DERIVATIVES | PFIZER INC. (US) | 2005-07-14 | — | — | WO | claimed |
| US-20050137395-A1 | Novel quinoline derivatives | AGOURON PHARMACEUTICALS, INC. | 2005-06-23 | — | — | US | claimed |
| US-7923457-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923457-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923457-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | AGOURON PHARMACEUTICALS, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | AGOURON PHARMACEUTICALS, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | AGOURON PHARMACEUTICALS, INC. | 2009-03-12 | — | — | US | disclosed |
| US-7381824-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381824-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381824-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1699780-A1 | NOVEL QUINOLINE DERIVATIVES | Pfizer, Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005063739-A1 | NOVEL QUINOLINE DERIVATIVES | PFIZER INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050137395-A1 | Novel quinoline derivatives | AGOURON PHARMACEUTICALS, INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | COQ8B, COQ8A, MCM5 | HPGD 1234/4885MMP13 3656/4885LMNA 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.